Skip to content

Si ni er zhi tang in the treatment of depression state after breast cancer surgery of liver depression and kidney deficiency type: A prospective, single center, randomized controlled trial

Si ni er zhi tang in the treatment of depression state after breast cancer surgery of liver depression and kidney deficiency type: A prospective, single center, randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000267
Enrollment
Unknown
Registered
2024-08-20
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression state after breast cancer surgery

Interventions

treatment group:conventional treatment+oral granules of Si ni er zhi tang
control group:conventional treatment+fluoxetine hydrochloride capsules

Sponsors

Beijing Shijitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the medical diagnostic criteria for breast cancer and depressive states; (2) Have undergone surgical treatment for breast cancer; (3) Meet the diagnostic criteria of liver depression and kidney deficiency syndrome; (4) Women aged 18 to 80 years old;(5) Expected survival >3 months; (6) Not taking antipsychotic drugs for at least 2 weeks before treatment; (7) Being conscious and able to understand the content of the scale, voluntarily participating in the study and signing the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Are undergoing chemotherapy or have plans to undergo chemotherapy during the study period; (2) Suffering from an organic mental disorder or other physical illness that can lead to a depressive state; (3) Suffering from severe mental illness with recent self-harm or suicidal tendencies; (4) Abuse and dependence on psychoactive substances within the previous 3 months; (5) Diagnosed with other tumours; (6) Combined serious diseases of heart, brain, liver, kidney and haematopoietic system; (7) Pregnant, breastfeeding or pregnant women; (8) Allergy to the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
Hamilton rating scale for depression-24;

Secondary

MeasureTime frame
TNM staging of breast cancer;TCM syndrome score;Tumour marker;The Functional Assessment of Cancer Therapy - Breast scale;

Countries

China

Contacts

Public ContactMin Jiang

Beijing Shijitan Hospital, Capital Medical University

jiangm1965@sina.com13311108797

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026